ATHOS

Athos Therapeutics Announces Proteomics Research Collaboration for Inflammatory Bowel Disease with Caltech

Retrieved on: 
Thursday, August 25, 2022
CEO, Sex, Cancer, FACS, Autoimmune disease, Enzalutamide, Degenerative disease, Therapy, Mission, Doctor of Philosophy, Artificial intelligence, Inflammatory bowel disease, Protein, Disease, Proteome, Blood, IBD, LOS, Multimedia, MBA, Company, FDA, Biomarker, MS, Kite Pharma, Proteomics, Patient, CMO, Medical imaging, Medical device, Pharmaceutical industry, California Institute of Technology, MD

LOS ANGELES, Aug. 25, 2022 /PRNewswire/ -- Athos Therapeutics, Inc. ("Athos") is a late-stage preclinical biotech company using Artificial Intelligence (AI) to develop small molecule therapeutics for immune-mediated diseases and cancer. Athos announced today that they will be enhancing their internal omics AI platform by adding proteomics analysis in collaboration with Caltech. This collaboration will advance both the Athos platform and spectrometry-based proteomics in the field of Inflammatory Bowel Disease.

Key Points: 
  • Athos announced today that they will be enhancing their internal omics AI platform by adding proteomics analysis in collaboration with Caltech.
  • This collaboration will advance both the Athos platform and spectrometry-based proteomics in the field of Inflammatory Bowel Disease.
  • Athos and Caltech will perform spectrometry-based proteomics using cultured cells and biopsies from archived and de-identified IBD patient samples.
  • "We are excited to collaborate with Dr. Chou's proteomics research team at Caltech," said Dimitrios Iliopoulos, PhD, MBA, President & CEO of Athos.

Athos Therapeutics Announces Research Collaboration to Advance Precision Medicine in Inflammatory Bowel Disease

Retrieved on: 
Monday, July 11, 2022
Biology, Inflammatory bowel disease, FDA, CEO, Lahey Hospital & Medical Center, Therapy, Precision medicine, Inflammatory Bowel Diseases, Disease, IBD, Enzalutamide, Doctor of Philosophy, CMO, CD, Sex, Division, Company, Crohn's disease, FACS, Ulcerative colitis, MS, Intelligence, Multimedia, Kite Pharma, Degenerative disease, Mission, Cancer, Autoimmune disease, Patient, Research, LOS, UC, Medical Center, MBA, Medical imaging, Pharmaceutical industry, Gastroenterology, MD

 LOS ANGELES, July 11, 2022 /PRNewswire/ -- Athos Therapeutics, Inc. ("Athos"), a late-stage preclinical biotech company using artificial intelligence to develop small molecule therapeutics for immune-mediated diseases and cancer, announced today a comprehensive Master Research Agreement for a collaborative project on Inflammatory Bowel Disease (IBD) with Lahey Hospital & Medical Center ("Lahey"). This collaboration will advance systems biology and computational analyses in the field of Inflammatory Bowel Diseases (IBD).

Key Points: 
  • Athos to perform molecular analysis of biopsies from de-identified Inflammatory Bowel Disease patient samples from Lahey Hospital & Medical Center based in Burlington, Massachusetts.
  • LOS ANGELES, July 11, 2022 /PRNewswire/ -- Athos Therapeutics, Inc. ("Athos"), a late-stage preclinical biotech company using artificial intelligence to develop small molecule therapeutics for immune-mediated diseases and cancer, announced today a comprehensive Master Research Agreement for a collaborative project on Inflammatory Bowel Disease (IBD) with Lahey Hospital & Medical Center("Lahey").
  • This collaboration will advance systems biology and computational analyses in the field of Inflammatory Bowel Diseases (IBD).
  • "We are very excited about our research initiatives with Athos Therapeutics," said Randall Pellish, MD, Director, Lahey Inflammatory Bowel Disease Center, Division of Gastroenterology, Lahey Hospital and Medical Center.

Yiannis Monovoukas and Monte Stettin, Noted Executives and Entrepreneurs, Appointed as Advisors and Observers to the Board of Directors of Athos Therapeutics

Retrieved on: 
Tuesday, May 31, 2022
MBA, Software, Company, History, Partner (business rank), Disease, Enzalutamide, Stanford University, Falcon, Doctor of Philosophy, Kite Pharma, Director, Degenerative disease, Leadership, Chemical engineering, Pleasure, Szczecin, Patient, Multimedia, New England, List of life sciences, Therapy, Clinical trial, Singularity University, FDA, MS, Board, Autoimmune disease, Technology, Board of directors, Advertising, FACS, Monte, CMO, Harvard Business School, Intelligence, Founder, The Company, Cancer, CEO, Pharmaceutical industry, Management, MD

"I am delighted to join the Athos Board of Directors as an observer," said Dr. Monovoukas.

Key Points: 
  • "I am delighted to join the Athos Board of Directors as an observer," said Dr. Monovoukas.
  • The Athos team has developed an impressive platform technology and I look forward to assisting them with future strategic options."
  • "It is a great privilege to join the Athos team in an advisory role and join as a Board of Directors Observer," said Mr. Stettin.
  • "We are very pleased to welcome Yiannis Monovoukas and Monte Stettin as observers to our Board of Directors," said Allan Pantuck, MD, MS, FACS, Chairman, Founder & CMO.

Abraham Verghese MD, Noted Stanford Physician and Recipient of the National Humanities Medal at the White House from former President Obama, Appointed to the Board of Directors of Athos Therapeutics

Retrieved on: 
Wednesday, May 18, 2022
Linda, Department, Physician, Inflammation, American Academy, The New Yorker, Company, Disease, Enzalutamide, Medicine, Stanford University School of Medicine, White House, Pulmonology, National Humanities Medal, Doctor of Philosophy, Kite Pharma, Degenerative disease, Multimedia, Patient, Infection, The New York Times, Therapy, National Academy of Medicine, National academy, Caregiver, FDA, Compugen (Israeli company), MS, PhD-MBA, Board, Department of Medicine – University of Pamplona, Autoimmune disease, Board of directors, Drug development, FACS, White, CMO, Intelligence, MACP, New Yorker, The Company, Cancer, Science, Stanford University, CEO, Cutting for Stone, Pharmaceutical industry, Granta, MD

"I am honored to join the Athos Board of Directors," said Dr. Verghese.

Key Points: 
  • "I am honored to join the Athos Board of Directors," said Dr. Verghese.
  • "Dr. Verghese is a highly distinguished physician, humanist, administrator, and adviser.
  • Abraham Verghese MD is the Linda R. Meier and Joan F. Lane Provostial Professor, and Vice Chair of the Department of Medicine at Stanford University School of Medicine.
  • He is a recipient of the National Humanities Medal at the White House from former President Obama.

Athos Group Expands Advisory Council of Law Enforcement Experts

Retrieved on: 
Wednesday, May 4, 2022
Professional Services, Data Management, Public Policy, Government, Law Enforcement, Emergency Services, Other Professional Services, Technology, Software, Insurance, Axon, Software, Time, Boston Police Department, Adoption, Yoy, John Isner, Police, Technology, Multimedia, Drug, Management, Passport, Motorola

The Athos Group, a leader in law enforcement services, is expanding its advisory board to include Jorge Colina, former Miami Police Chief, and Joshua Isner, Chief Revenue Officer at Axon.

Key Points: 
  • The Athos Group, a leader in law enforcement services, is expanding its advisory board to include Jorge Colina, former Miami Police Chief, and Joshua Isner, Chief Revenue Officer at Axon.
  • The expansion is prompted by the increased adoption and 360% YoY growth of RollKall, owned by Athos Group.
  • Isner and Colina will be working with the Athos board to identify ways to support and serve law enforcement with future iterations of the RollKall platform and how it can assist law enforcement agencies throughout the country.
  • Athos Group provides standards and services in the off-duty and extra-duty security and law enforcement industries.

Alvotech Upsizes Oversubscribed PIPE Transaction to Approximately $175 Million

Retrieved on: 
Tuesday, January 18, 2022
Professional Services, Oncology, Health, Finance, Pharmaceutical, Biotechnology, U.S. Securities and Exchange Commission, Forward-looking statement, Patient, Annual report, Name, PIPE, Person, Business architecture, SEC, CVC Capital Partners, Registration statement, Oaktree Capital Management, Landsbankinn, NYSE, Growth, NASDAQ, CEO, Acquisition, Goal, Temasek Holdings, Farallon Capital, Degenerative disease, Form, Arion Bank, Sale, Cancer, Communication, Risk, Sculptor Capital Management, Register, Business, Osteoporosis, Securities Act of 1933, Failure, Prospectus, Terminology, Family office, Fine chemical, Security (finance), Risk management

The upsized PIPE, totaling approximately $175 million and entirely raised as common stock at $10.00 per share, is driven by increased interest from premier Icelandic investors, including Arctica Finance, Arion Bank, and Landsbankinn.

Key Points: 
  • The upsized PIPE, totaling approximately $175 million and entirely raised as common stock at $10.00 per share, is driven by increased interest from premier Icelandic investors, including Arctica Finance, Arion Bank, and Landsbankinn.
  • The business combination is expected to deliver gross proceeds to Alvotech in excess of $475 million (assuming no redemptions).
  • This includes cash proceeds of approximately $250 million from Oaktree IIs trust account (assuming no redemptions); in excess of $175 million from the upsized (PIPE) investors; and a $50 million equity commitment from existing shareholders which funded before year-end 2021.
  • Alvotech is well positioned to continue investing in the global growth of our biosimilar pipeline, remarked Mark Levick, CEO of Alvotech.

Alvotech and Oaktree Acquisition Corp. II Announce Merger Agreement to Create a Leading Publicly-Traded Global Biopharmaceutical Company

Retrieved on: 
Tuesday, December 7, 2021
Biotechnology, General Health, Pharmaceutical, Health, Alvotech, Oaktree Acquisition Corp. II, Oaktree Life Sciences Lending, ALVOTECH, OAKTREE ACQUISITION CORP. II, OAKTREE LIFE SCIENCES LENDING

Alvotech Holdings S.A. (Alvotech), a leading global biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients worldwide, and Oaktree Acquisition Corp. II (NYSE: OACB.U, OACB, OACB WS), a special purpose acquisition company sponsored by an affiliate of Oaktree Capital Management, L.P. (Oaktree), announced today that they have entered into a definitive merger agreement.

Key Points: 
  • Alvotech Holdings S.A. (Alvotech), a leading global biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients worldwide, and Oaktree Acquisition Corp. II (NYSE: OACB.U, OACB, OACB WS), a special purpose acquisition company sponsored by an affiliate of Oaktree Capital Management, L.P. (Oaktree), announced today that they have entered into a definitive merger agreement.
  • Alvotech aims to become a leading supplier of biosimilar medicines in all major markets around the world.
  • In order to give its products global reach, Alvotech has formed strategic commercialization partnerships covering 60+ countries with leading pharmaceutical companies.
  • A presentation made by the management teams each of Alvotech and Oaktree Acquisition Corp. II regarding the transaction will be available on the websites of Oaktree Acquisition Corp. II at https://www.oaktreeacquisitioncorp.com/news and Alvotech at https://www.alvotech.com/newsroom .

Bill.com Hires Experienced Brand-Builder Sarah Acton as Chief Marketing Officer

Retrieved on: 
Thursday, December 2, 2021
Professional Services, Technology, Software, Finance, Internet, Banking, Accounting, Adoption, CEO, Department of Defense Cyber Crime Center, Â, NYSE, Marketing, Mentorship, Leadership, Founder, Entrepreneurship, Department, Yahoo!, Love, CA, Super Mario, LinkedIn, Multimedia, Tulane University, Growth, Management, Public relations

Bill.com (NYSE:BILL), a leading provider of cloud-based software that simplifies, digitizes, and automates back-office financial processes for small and midsized businesses (SMBs), announced today that Sarah Acton has joined the company as Chief Marketing Officer.

Key Points: 
  • Bill.com (NYSE:BILL), a leading provider of cloud-based software that simplifies, digitizes, and automates back-office financial processes for small and midsized businesses (SMBs), announced today that Sarah Acton has joined the company as Chief Marketing Officer.
  • We are thrilled to welcome Sarah to Bill.com where she will accelerate our marketing and brand-building efforts.
  • Sarah was also responsible for global brand oversight during pivotal periods of growth at LinkedIn and consumer marketing leadership at Yahoo!.
  • It is a gift as a marketing leader to work for a company that has such a rich story supporting SMBs, said Sarah Acton, Chief Marketing Officer at Bill.com.

Athos Therapeutics Announces their Corporate Circle Membership to the Crohn's & Colitis Foundation and Participation in the "IBD Innovate" Conference

Retrieved on: 
Wednesday, October 13, 2021
Business development, MBA, Crohn's disease, Senior, Cancer, Ulcerative colitis, Enzalutamide, Foundation, Doctor of Philosophy, Precision medicine, Crohn's & Colitis Foundation, IBD, CCF, Therapy, MS, FDA, Multimedia, Patient, Systems biology, Degenerative disease, Company, Kite Pharma, Inflammatory bowel disease, Research, Oklahoma Office of the Chief Medical Examiner, Quality of life, Pharmaceutical industry

At the IBD INNOVATE: Product Development for Crohn's & Colitis conference ( https://www.crohnscolitisfoundation.org/ibd-innovate )Athos will be presenting exciting new data regarding its innovative platform to develop precision medicine therapeutics for IBD patients.

Key Points: 
  • At the IBD INNOVATE: Product Development for Crohn's & Colitis conference ( https://www.crohnscolitisfoundation.org/ibd-innovate )Athos will be presenting exciting new data regarding its innovative platform to develop precision medicine therapeutics for IBD patients.
  • The Company is developing precision therapeutics by the stratification of IBD patients into specific molecular subtypes.
  • "Our membership with the Crohn's & Colitis Foundation will enhance our collaborative efforts with the foundation, FDA, and other pharmaceutical companies to develop IBD precision therapeutics.
  • The Crohn's & Colitis Foundation is the leading non-profit organization focused on both research and patient support for inflammatory bowel disease (IBD).

Athos Therapeutics Announces Research Collaboration with Cleveland Clinic to Advance Precision Medicine in Inflammatory Bowel Disease

Retrieved on: 
Tuesday, August 24, 2021
Cancer, Company, MS, Cleveland Clinic, Kite Pharma, Therapy, Oklahoma Office of the Chief Medical Examiner, Immune system, History of Cleveland Clinic, Ulcerative colitis, Disease, Doctor of Philosophy, IBD, Lupus, Precision medicine, Multimedia, MBA, Pathology, Degenerative disease, Crohn's disease, Cleveland, Patient, Inflammatory bowel disease, FDA, Systems biology, M.D, Enzalutamide, Pharmaceutical industry

This approach can stratify IBD patients into specific molecular subtypes and enable the development of precision (custom-made) therapeutics.

Key Points: 
  • This approach can stratify IBD patients into specific molecular subtypes and enable the development of precision (custom-made) therapeutics.
  • "Cleveland Clinic is internationally recognized as a leader in the care of patients with IBD," said Claudio Fiocchi, M.D, of Cleveland Clinic's Lerner Research Institute.
  • "This collaborative research will help to implement precision medicine for patients with Crohn's disease and ulcerative colitis."
  • Athos Therapeutics Inc. is a late-stage preclinical biotech company developing small molecule therapeutics for immune-mediated diseases using artificial intelligence-generated innovativechemistry and computational platforms.